EU IVDR Audit Bottlenecks Are Redrawing Market Access

IVDR enforcement is shifting European IVD competition from product claims to audit capacity, documentation quality, and certification readiness.

Updated

What is this trend?

EU IVDR is turning notified-body audits, technical documentation, and lab testing into the main gatekeepers of IVD market access, favoring companies that can prove compliance at scale.

  • Class B/C/D devices now face deeper notified-body scrutiny, with Class D adding EU reference lab batch-release testing.
  • Extended-transition access depends on formal applications, signed agreements, and audit-ready quality systems.
  • Classification discipline and complete technical files matter as much as assay performance.
  • Audit capacity is becoming a market constraint, reshaping which products stay certified and purchasable.
  • The same compliance-first logic is spreading across reimbursement and supplier approval decisions.

What’s the latest?

EU IVDR readiness turned into a hard commercial gate this week: Class B, C, and D devices now face deeper notified-body involvement, with Class C requiring a full quality-system audit and Class D addi

Workflow-embedded diagnostics win, EU access bottlenecks tighten, and biomarker evidence becomes the moat

How it developed

  1. Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercialization
    • FDA-Cleared Claims Are Becoming Commercial Moats

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.